Sonoma Pharmaceuticals (SNOA) Revenue (2010 - 2026)

Sonoma Pharmaceuticals (SNOA) has reported Revenue for 17 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 48.14% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $19.5 million (up 36.68% YoY), while the FY2026 annual figure was $19.5 million, up 36.68% from the prior year.
• Revenue came in at $5.6 million for Q1 2026 at Sonoma Pharmaceuticals, up from $4.3 million in the prior quarter.
• The five-year high for Revenue was $5.6 million in Q3 2025, with the low at $2.3 million in Q1 2022.
• Average Revenue over 5 years is $3.7 million, with a median of $3.4 million recorded in 2024.
• Across the five-year window, Revenue slipped 18.01% in 2023 and jumped 56.58% in 2025, its largest moves.
• Year by year, Revenue stood at $2.9 million in 2022, then grew by 6.59% to $3.1 million in 2023, then advanced by 13.58% to $3.6 million in 2024, then grew by 22.03% to $4.3 million in 2025, then advanced by 27.87% to $5.6 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $5.6 million, $4.3 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.